FrontPoint Health Care Investors Flee

Nov 9 2010 | 12:37pm ET

FrontPoint Partners has seen investors in its health care funds race for the doors in the wake of their link to an insider-trading case.

Clients have filed redemption requests totaling about half of the $750 million managed by the funds, which FrontPoint has admitted are among the unidentified hedge funds referred to in the case against Yves Benhamou. Benhamou was arrested last week and charged with passing on confidential information about the results of a drug trial to the funds.

That information allegedly enabled FrontPoint to escape $30 million in losses it would have suffered after the negative information about the hepatitis-C drug became public. Neither FrontPoint nor Morgan Stanley, which is spinning off the hedge fund, have been accused of any wrongdoing. But the firm has placed the health care funds' lead portfolio manager, Joseph Skowron, on leave; Skowron is believed to be the unidentified "co-portfolio manager" who allegedly received the tip from Benhamou, a former adviser to pharmaceutical company Human Genome Sciences, the maker of the drug.

FrontPoint has also decided to give investors in Skowron's funds an extra two weeks to decide whether or not to flee, extending the deadline for Dec. 31 redemption requests from Nov. 15 to Dec. 1, Reuters reports.

According to The Wall Street Journal, FrontPoint and Morgan Stanley executives, including FrontPoint co-CEO Michael Kelly, had warned Skowron about trading company stocks that he and his team had discussed with their network of health-care advisers, of whom Benhamou was one. Kelly reportedly told Skowron to be cautious about who he spoke to and how their information factored into his trading decisions.

Others at FrontPoint questioned whether some of those advisers were investors with FrontPoint, creating a potential conflict of interest. The increased scrutiny of Skowron's activities came after Morgan Stanley and FrontPoint learned two years ago that the Securities and Exchange Commission was looking into the hedge fund's Human Genome trades.


In Depth

Why Ponzi Schemes Work: An In-Depth Look At The Allen Stanford Fraud

Dec 21 2014 | 10:30am ET

Texan Allen Stanford first appeared on the radars of financial regulators in 1997...

Lifestyle

Hedgie Funds US Squash Program

Dec 24 2014 | 8:46am ET

Squash, anyone?

Guest Contributor

EidoSearch’s Top Three Market Projections For 2015

Dec 23 2014 | 4:03am ET

It is that time of year again when prognosticators make their big market calls for...

 

Sponsored Content

Editor's Note

    Guidelines for Guest Articles

    Oct 22 2014 | 9:46am ET

    We are always looking for guest articles from hedge fund managers and buy-side firms.

    If you are interested in submitting a contributed piece for possible publication on FINalternatives, please take a look at the specs. Read more…

 

Futures Magazine

December 2014 Cover

Futures 2014 person of the year

Jeff Sprecher was simply looking for a platform to trade energies when launching ICE 14 years ago but it has grown to reach the pinnacle of both the listed futures and equities world.

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.